Clinical Trials Browser

Phase 3 × Solid Tumor × Erlotinib Hydrochloride × Clear all

NCT02488330 2019-07-23

An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study

Phase 3 Completed

12 enrolled 8 charts

Other solid neoplasm

Solid Tumor